| Year |
Citation |
Score |
| 2005 |
De Souza AP, Cohen AW, Park DS, Woodman SE, Tang B, Gutstein DE, Factor SM, Tanowitz HB, Lisanti MP, Jelicks LA. MR imaging of caveolin gene-specific alterations in right ventricular wall thickness. Magnetic Resonance Imaging. 23: 61-8. PMID 15733789 DOI: 10.1016/J.Mri.2004.11.011 |
0.553 |
|
| 2004 |
Woodman SE, Sotgia F, Galbiati F, Minetti C, Lisanti MP. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology. 62: 538-43. PMID 14981167 DOI: 10.1212/Wnl.62.4.538 |
0.543 |
|
| 2004 |
Woodman SE, Cheung MW, Tarr M, North AC, Schubert W, Lagaud G, Marks CB, Russell RG, Hassan GS, Factor SM, Christ GJ, Lisanti MP. Urogenital alterations in aged male caveolin-1 knockout mice. The Journal of Urology. 171: 950-7. PMID 14713860 DOI: 10.1097/01.Ju.0000105102.72295.B8 |
0.755 |
|
| 2003 |
Sotgia F, Bonuccelli G, Minetti C, Woodman SE, Capozza F, Kemp RG, Scherer PE, Lisanti MP. Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases. The American Journal of Pathology. 163: 2619-34. PMID 14633633 DOI: 10.1016/S0002-9440(10)63616-4 |
0.551 |
|
| 2003 |
Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, Lisanti MP. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. The American Journal of Pathology. 163: 1663-75. PMID 14507673 DOI: 10.1016/S0002-9440(10)63523-7 |
0.751 |
|
| 2003 |
Sotgia F, Woodman SE, Bonuccelli G, Capozza F, Minetti C, Scherer PE, Lisanti MP. Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease. American Journal of Physiology. Cell Physiology. 285: C1150-60. PMID 12839838 DOI: 10.1152/Ajpcell.00166.2003 |
0.504 |
|
| 2003 |
Woodman SE, Ashton AW, Schubert W, Lee H, Williams TM, Medina FA, Wyckoff JB, Combs TP, Lisanti MP. Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. The American Journal of Pathology. 162: 2059-68. PMID 12759260 DOI: 10.1016/S0002-9440(10)64337-4 |
0.713 |
|
| 2003 |
Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolin, caveolae, and endothelial cell function. Arteriosclerosis, Thrombosis, and Vascular Biology. 23: 1161-8. PMID 12689915 DOI: 10.1161/01.Atv.0000070546.16946.3A |
0.687 |
|
| 2003 |
Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, et al. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. American Journal of Physiology. Cell Physiology. 284: C457-74. PMID 12388077 DOI: 10.1152/Ajpcell.00380.2002 |
0.623 |
|
| 2002 |
Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacological Reviews. 54: 431-67. PMID 12223531 DOI: 10.1124/Pr.54.3.431 |
0.641 |
|
| 2002 |
Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, Lisanti MP. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. The Journal of Biological Chemistry. 277: 40091-8. PMID 12167625 DOI: 10.1074/Jbc.M205948200 |
0.762 |
|
| 2002 |
Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, Factor SM, Tanowitz HB, Lisanti MP. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. The Journal of Biological Chemistry. 277: 38988-97. PMID 12138167 DOI: 10.1074/Jbc.M205511200 |
0.634 |
|
| 2002 |
Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, Chandra M, Shirani J, Razani B, Tang B, Jelicks LA, Factor SM, Weiss LM, Tanowitz HB, Lisanti MP. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. The American Journal of Pathology. 160: 2207-17. PMID 12057923 DOI: 10.1016/S0002-9440(10)61168-6 |
0.741 |
|
| 2002 |
Woodman SE, Schlegel A, Cohen AW, Lisanti MP. Mutational analysis identifies a short atypical membrane attachment sequence (KYWFYR) within caveolin-1. Biochemistry. 41: 3790-5. PMID 11888297 DOI: 10.1021/Bi0120751 |
0.612 |
|
| 2001 |
Lee H, Woodman SE, Engelman JA, Volonté D, Galbiati F, Kaufman HL, Lublin DM, Lisanti MP. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (TYR-14). The Journal of Biological Chemistry. 276: 35150-8. PMID 11451957 DOI: 10.1074/Jbc.M104530200 |
0.646 |
|
| Show low-probability matches. |